Get started
Work

Randomized, Dose-Ranging Phase Ii Trial of Nivolumab for Metastatic Renal Cell Carcinoma (Mrcc)

Year: 2014
Type: article
Study design: Clinical Trial
DOI: 10.1093/annonc/mdu337.3
Authors: R.J. Motzer, B.I. Rini, D.F. McDermott, B. Redman, T. Kuzel, M.R. Harrison, U.N. Vaishampayan, H. Drabkin, S. George, T. Logan, K. Margolin, E.R. Plimack, I. Waxman, A. Lambert, H. Hammers
Institutions: Memorial Sloan Kettering Cancer Center, Cleveland Clinic, Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center, University of Michigan, U-M Rogel Cancer Center, Northwestern University, Duke University, Duke Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Medical University of South Carolina, Roswell Park Comprehensive Cancer Center, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Seattle Cancer Care Alliance, Fox Chase Cancer Center, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Belgium), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Language: English
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Celgene, Exelixis, Acceleron, Astellas Pharma, Genentech
OpenAlex ID: W2272911915
FWCI: 0.727
Cites:
Cited by: 4
Related to: 10